07:00 , Apr 21, 2008 |  BioCentury  |  Strategy

Celgene pipeline

Celgene pipeline Compound Description Indication Status From Orplatna satraplatin [partner: GPC] Oral platinum compound 2nd line hormone-refractory prostate cancer (HRPC) Under review in EU Pharmion Amrubicin Third-generation synthetic anthracycline Small cell lung...
07:00 , Apr 21, 2008 |  BioCentury  |  Strategy

Celgene's 2020 foresight

Over the last few months, Celgene Corp. has spent some $3 billion to expand its pipeline of hematology/oncology products via one large acquisition and a series of three collaborations. The goal is to keep its...